Translational oncotargets for immunotherapy: From pet dogs to humans

Preclinical studies in rodent models have been a pivotal role in human clinical research, but many of them fail in the translational process. Spontaneous tumors in pet dogs have the potential to bridge the gap between preclinical models and human clinical trials. Their natural occurrence in an immunocompetent system overcome the limitations of preclinical rodent models. Due to its reasonable cellular, molecular, and genetic homology to humans, the pet dog represents a valuable model to accelerate the translation of preclinical studies to clinical trials in humans, actually with benefits for both species. Moreover, their unique genetic features of breeding and breed-related mutations have contributed to assess and optimize therapeutics in individuals with different genetic backgrounds. This review aims to outline four main immunotherapy approaches-cancer vaccines, adaptive T-cell transfer, antibodies, and cytokines -, under research in veterinary medicine and how they can serve the clinical application crosstalk with humans. (c) 2021 Elsevier B.V. All rights reserved.

Automated summary

Spontaneous tumors in pet dogs can serve as a valuable model to bridge the gap between preclinical models and human clinical trials, due to their similar cellular, molecular, and genetic characteristics with humans. This model can accelerate the translation of preclinical studies to clinical trials, benefiting both species.